With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.

Propelled by a flurry of dealmaking late in the year, M&As in 2025 ended on a strong note, with high activity expected to ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer ...

(Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer to end a fierce bidding war between the pharma giant ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million in value and announced this year. M&A, however, has not been enough for ...

The deal focuses on a weight-loss pill in development at YaoPharma, a GLP-1 agonist codenamed YP05002, which is currently in ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Metsera was the target of a bidding war by pharma giants. The company has an innovative obesity drug candidate. 10 stocks we like better than Metsera › Innovative biopharmaceutical company Metsera ...

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in ...